J Korean Med Assoc.  2010 Mar;53(3):228-235. 10.5124/jkma.2010.53.3.228.

Current Management of Peripheral Arterial Disease

• Choi SH

• KMID: 1775334
• DOI: http://doi.org/10.5124/jkma.2010.53.3.228

Abstract

Peripheral arterial disease (PAD) is defined as atherosclerotic disease of infrarenal aorta and arteries of the lower extremities. PAD is a frequent but underdiagnosed and undertreated disease with substantial cardiovascular morbidity and mortality. Accordingly, early recognition of PAD is crucial to initiation of therapy. The ankle-brachial index (ABI) is a simple, inexpensive and noninvasive test to confirm the diagnosis of PAD and also provides risk stratification for the future cardiovascular events. Therefore, ABI should be measured in all patients with suspected PAD. Lifestyle adjustment and supervised exercise program are a major support for the therapy. Modification of treatable risk factors in conjunction with antiplatelet therapy improves cardiovascular outcomes. Cilostazol can be used as the first-line pharmacotherapy agent for the relief of claudication symptoms. Mechanical revascularization should be reserved for patients with critical limb ischemia or lifestyle limiting claudication. Remarkable technological advances in endovascular treatment have shifted revascularization strategies from traditional open surgery toward lower-morbidity percutaneous endovascular treatments. The novel therapies for increasing pain-free walking distance are under investigation. Above all, improved awareness and education in both primary physicians and the patients with cardiovascular risk factors can decrease morbidity and mortality secondary to atherosclerotic vascular disease.

Keyword

Peripheral arterial disease; Ankle-brachial index; Revascularization

MeSH Terms

Ankle Brachial Index
Aorta
Arteries
Extremities
Humans
Ischemia
Life Style
Lower Extremity
Oxalates
Peripheral Arterial Disease
Risk Factors
Tetrazoles
Vascular Diseases
Walking
Oxalates
Tetrazoles

Figure

• 

  Figure 1 Algorithm of treatment of patients with proven PAD.

Reference

1. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004. 110:738–742.

2. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001. 286:1317–1324.

3. Choi DH, Pyun WB, Yoon YS, Jang Y, Shim WH. Frequency of Combined Atherosclerotic Disease of the Coronary, Periphery, and Carotid Arteries Found by Angiography. Korean Circ J. 1999. 29:883–890.

4. Becker GJ, McClenny TE, Kovacs ME, Raabe RD, Katzen BT. The importance of increasing public and physician awareness of peripheral arterial disease. J Vasc Interv Radiol. 2002. 13:7–11.

5. Lu JT, Creager MA. The relationship of cigarette smoking to peripheral arterial disease. Cardiovasc Med. 2004. 5:189–193.

6. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epedimiology, pathophysiology, and management. JAMA. 2002. 287:2570–2581.

7. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006. 113:e463–e654.

8. Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008. 300:197–208.

9. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Rutherford RB. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007. 45:S5–S67.

10. Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation. 2006. 113:2623–2629.

11. Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med. 2006. 144:660–664.

12. Radack K, Deck C. β-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Intern Med. 1991. 151:1769–1776.

13. Creasy TS, McMillan PJ, Fletcher EW, Collin J, Morris PJ. Is percutaneous transluminal angioplasty better than exercise for claudication? Preliminary results from a prospective randomised trial. Eur J Vasc Surg. 1990. 4:135–140.

14. Lundgren F, Dahllof AG, Lundholm K, Schersten T, Volkmann R. Intermittent claudication-surgical reconstruction or physical training? a prospective randomized trial of treatment efficiency. Ann Surg. 1989. 209:346–355.

15. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996. 348:1329–1339.

16. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002. 90:1314–1319.

17. Coffman JD. Drug therapy: vasodilator drugs in peripheral vascular disease. N Engl J Med. 1979. 300:713–717.

18. Hansen PR, Holm AM, Qi JH, Ledet T, Rasmussen LM, Andersen CB. Pentoxifylline inhibits neointimal formation and stimulates constrictive vascular remodeling after arterial injury. J Cardiovasc Pharmacol. 1999. 34:683–689.

19. Girolami B, Bernardi E, Prins MH, Ten Cate JW, Hettiarachchi R, Prandoni P, Girolami A, Büuller HR. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med. 1999. 159:337–345.

20. Lehert P, Comte S, Gamand S, Brown TM. Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol. 1994. 23:S48–S52.

21. Avellone G, Mandalá V, Pinto A, Martino A, Strano A. Clinical evaluation of short-term defibrotide treatment of patients with atherosclerosis obliterans of the lower limbs. Haemostasis. 1986. 16:55–58.

22. Brass EP, Anthony R, Cobb FR, Koda I, Jiao J, Hiatt WR. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006. 48:2539–2545.

23. Nenci GG, Gresele P, Ferrari G, Santoro L, Gianese F. Mesoglycan Intermittent Claudication group. Treatment of intermittent claudication with mesoglycan-a placebo-controlled, double-blind study. Thromb Haemost. 2001. 86:1181–1187.

24. Takeshita S, Zheung LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, Isner JM. Therapeutic angiogenesis: A single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hindlimb model. J Clin Invest. 1994. 93:662–670.

25. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, Annex BH. TRAFFIC investigators. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomized trial. Lancet. 2002. 359:2053–2058.

26. Rajagopalan S, Mohler ER III, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003. 108:1933–1938.

27. Murphy TP, Ariaratnam NS, Carney WI, Marcaccio EJ, Slaiby JM, Soares GM, Kim HM. Aortoiliac insufficiency: long-term experience with stent placement for treatment. Radiology. 2004. 231:243–249.

28. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, Schlager O, Cejna M, Lammer J, Minar E. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006. 354:1879–1888.

29. Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, Loewe C, Cejna M, Lammer J, Minar E. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007. 115:2745–2749.

30. Scheinert D, Scheinert S, Sax J, Piorkowski C, Bräaunlich S, Ulrich M, Biamino G, Schmidt A. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005. 45:312–315.

31. Fischer M, Schwabe C, Schulte KL. Value of the hemobahn/viabahn endoprosthesis in the treatment of long chronic lesions of the superficial femoral artery: 6 years of experience. J Endovasc Ther. 2006. 13:281–290.

32. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008. 358:689–699.

33. Varty K, Bolia A, Naylor AR, Bell PR, London NJ. Infrapopliteal percutaneous transluminal angioplasty: a safe and successful procedure. Eur J Vasc Endovasc Surg. 1995. 9:341–345.

34. Ingle H, Nasim A, Bolia A, Fishwick G, Naylor R, Bell PR, Thompson MM. Subintimal angioplasty of isolated infragenicular vessels in lower limb ischemia: long-term results. J Endovasc Ther. 2002. 9:411–416.

35. De Vries SO, Hunink MG. Results of aortic bifurcation grafts for aortoiliac occlusive disease: meta-analysis. J Vasc Surg. 1997. 26:558–569.

36. Veith FJ, Gupta SK, Ascer E, Ingle H, Nasim A, Bolia A, White-Flores S, Samson RH, Scher LA, Towne JB, Bernhard VM, Bonier P, Flinn WR, Astelford P, Yao JS, Bergan JJ. Six-year prospective multicenterrandomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg. 1986. 3:104–114.